EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical Evaluation of the Efficacy of α-Difluoromethylornithine and Sulindac Against SARS-CoV-2 Infection

Natalia A Ignatenko iD, Hien T Trinh iD, April M Wagner iD, Eugene W Gerner, Christian Bime, Chiu-Hsieh Hsu, David G Besselsen iD

Viruses · 2025

DOI: 10.3390/v17101306 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Natalia A Ignatenko und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular and Molecular Medicine, The University of Arizona, Tucson, AZ 85724, USA. Hauptthemen laut MEDLINE: Eflornithine, Sulindac, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite numerous research efforts and several effective vaccines and therapies developed against coronavirus disease 2019 (COVID-19), drug repurposing remains an attractive alternative approach for treatment of SARS-CoV-2 variants and other viral infections that may emerge in the future. Cellular polyamines support viral propagation and tumor growth. Here we tested the antiviral activity of two polyamine metabolism-targeting drugs, an irreversible inhibitor of polyamine biosynthesis, α-difluoromethylornithine (DFMO), and a non-steroidal anti-inflammatory drug (NSAID), Sulindac, which have been previously evaluated for colon cancer chemoprevention. The drugs were tested as single agents and in combination in the human Calu-3 lung adenocarcinoma and Caco-2 colon adenocarcinoma cell lines and the K18-hACE2 transgenic mouse model of severe COVID-19. In the infected human cell lines, the DFMO/Sulindac combination significantly suppressed SARS-CoV-2 N1 Nucleocapsid mRNA by interacting synergistically when cells were pretreated with drugs and additively when treatment was applied to the infected cells. The Sulindac alone and DFMO/Sulindac combination treatments also suppressed the expression of the viral Spike protein and the host angiotensin-converting enzyme 2 (ACE2). In K18-hACE2 mice, the antiviral activity of DFMO and Sulindac as single agents and in combination was tested as prophylaxis (drug supplementation started 7 days before infection) or as treatment (drug supplementation started 24 h post-infection) at the doses equivalent to patient chemoprevention trials (835 ppm DFMO and 167 ppm Sulindac). The drugs’ antiviral activity in vivo was evaluated by measuring the clinical (survival rates and clinical scores), viral (viral load and virus infectivity), and biochemical (plasma polyamine, Sulindac, and Sulindac metabolite levels) endpoints. Prophylaxis with DFMO and Sulindac as single agents significantly increased survival rates in the young male mice (p = 0.01 and p = 0.027, respectively), and the combination was effective in the aged male mice (p = 0.042). Young female mice benefited the most from the prophylaxis with Sulindac alone (p = 0.001) and the DFMO/Sulindac combination (p = 0.018), while aged female mice did not benefit significantly from any intervention. Treatment of SARS-CoV-2-infected animals with DFMO or/and Sulindac did not significantly improve their survival rates. Overall, our studies demonstrated that DFMO and Sulindac administration as the prophylaxis regimen provided strong protection against the lethal outcome of SARS-CoV-2 infection and that male mice benefited more from the polyamine-targeted antiviral treatment than female mice. Our findings underscore the importance of evaluation of the antiviral activity of the drugs in the context of sex and age.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EflornithineSulindacAntiviral AgentsCOVID-19 Drug TreatmentAnimalsHumansSARS-CoV-2MiceCOVID-19Disease Models, AnimalMice, TransgenicFemaleDrug Evaluation, PreclinicalCaco-2 CellsCell Line, Tumor

Stichwörter der Autor:innen

COVID-19 mouse modelDFMOSARS-CoV-2Sulindacantiviral drugspolyamines

Substanzen

EflornithineSulindacAntiviral Agents

Autor:innen und Institutionen

  • Department of Cellular and Molecular Medicine, The University of Arizona, Tucson, AZ 85724, USA.
  • Valley Fever Center for Excellence, The University of Arizona, Tucson, AZ 85724, USA.
  • University Animal Care, The University of Arizona, Tucson, AZ 85724, USA.
  • Department of Medicine, College of Medicine-Phoenix, The University of Arizona, Phoenix, AZ 85004, USA.
  • Mel and Enid Zuckerman College of Public Health, The University of Arizona, Tucson, AZ 85724, USA.

ORCID-Profile: Natalia A Ignatenko, Hien T Trinh, April M Wagner, David G Besselsen

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences

Zitieren

APA

Ignatenko, N. A., Trinh, H. T., Wagner, A. M., Gerner, E. W., Bime, C., Hsu, C. H., & Besselsen, D. G. (2025). Preclinical Evaluation of the Efficacy of α-Difluoromethylornithine and Sulindac Against SARS-CoV-2 Infection. Viruses. https://doi.org/10.3390/v17101306

Vancouver

Ignatenko NA, Trinh HT, Wagner AM, Gerner EW, Bime C, Hsu CH, et al. Preclinical Evaluation of the Efficacy of α-Difluoromethylornithine and Sulindac Against SARS-CoV-2 Infection. Viruses. 2025. doi:10.3390/v17101306

BibTeX
@article{Ignatenko2025,
  author = {Ignatenko, Natalia A and Trinh, Hien T and Wagner, April M and Gerner, Eugene W and Bime, Christian and Hsu, Chiu-Hsieh and Besselsen, David G},
  title = {Preclinical Evaluation of the Efficacy of α-Difluoromethylornithine and Sulindac Against SARS-CoV-2 Infection},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17101306}
}
Kostenlos starten →